- Report
- January 2026
- 190 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- July 2025
- 120 Pages
Global
From €5188EUR$5,950USD£4,511GBP
- Report
- March 2025
- 200 Pages
Global
From €3915EUR$4,490USD£3,404GBP
- Report
- February 2026
- 224 Pages
Global
From €5101EUR$5,850USD£4,435GBP
- Report
- January 2026
- 180 Pages
Global
From €3434EUR$3,939USD£2,986GBP
- Report
- February 2025
- 200 Pages
Global
From €3915EUR$4,490USD£3,404GBP
- Report
- February 2026
- 375 Pages
Global
From €5101EUR$5,850USD£4,435GBP
- Report
- November 2022
- 141 Pages
Global
From €4316EUR$4,950USD£3,753GBP
- Report
- March 2023
- 150 Pages
Global
From €5188EUR$5,950USD£4,511GBP
- Report
- October 2023
- 183 Pages
Global
From €3923EUR$4,500USD£3,412GBP
- Report
- April 2023
- 120 Pages
Global
From €4141EUR$4,750USD£3,601GBP
- Report
- May 2024
- 200 Pages
Global
From €3618EUR$4,150USD£3,146GBP
- Report
- April 2023
- 117 Pages
Global
From €4141EUR$4,750USD£3,601GBP
- Report
- April 2023
- 115 Pages
Global
From €4141EUR$4,750USD£3,601GBP
Hodgkin Lymphoma (HL) is a type of cancer that affects the lymphatic system, a part of the immune system. It is characterized by the presence of a type of cell called the Reed-Sternberg cell. HL is the most common type of lymphoma in the United States, and is most common in young adults. Treatment for HL typically involves chemotherapy, radiation therapy, and/or stem cell transplantation.
The oncology market for HL is highly competitive, with a number of companies offering treatments and therapies. These include pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, and Merck; biotechnology companies such as Gilead Sciences and Celgene; and medical device companies such as Medtronic and Stryker. Show Less Read more
